A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

This is an early-phase study testing a new drug called HLD-0915 in men with metastatic castration-resistant prostate cancer — meaning prostate cancer that has spread and is no longer responding to hormone-blocking treatments. **You may be eligible if...** - You are a man aged 18 or older - You have prostate cancer confirmed by biopsy - You have had surgical or medical hormone suppression (testosterone reduced to castrate levels) - Your cancer has continued to progress despite previous treatments - You are in reasonably good general health (able to carry out light activities) - Your life expectancy is at least 3 months - You have adequate kidney, liver, and blood count function **You may NOT be eligible if...** - You have significant heart, liver, or other major organ problems - You are receiving other active cancer treatments - You have untreated brain metastases Talk to your doctor to see if this trial is right for you.